Epigenetically, TRβ interacts with chromatin remodeling complexes and coregulators (e.g., BRD4, LSD1, HDAC1/2), suggesting that combining TRβ agonists with epigenetic inhibitors may synergistically reverse dedifferentiation and restore tumor suppressive programs [119]. The gene discussed is THRB; the disease is neoplasm.